Updated Jul 16, 2026 · Last SEC filing 2026-07-08
Kymera Therapeutics, Inc. (KYMR) has filed 28 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-08. 4 Form 8-K material event filings were reported by KYMR in the last 90 days. 32 Form 144 notices of proposed sale were filed for KYMR stock. InsiderAlpha tracks every KYMR SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001815442 |
| Form 4 filings (90d) | 28 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 32 |
| Latest Form 4 filing | 2026-07-08 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mainolfi Nello | Chief Executive Officer | M — Option exercise | 50.0K | $2.08 | $104K | SEC | |
| Mainolfi Nello | Chief Executive Officer | S — Open-market sale | 50.0K | $119.00 | $5.95M | SEC | |
| Mainolfi Nello | Chief Executive Officer | S — Open-market sale | 1.9K | $112.80 | $212K | SEC | |
| Mainolfi Nello | Chief Executive Officer | M — Option exercise | 80.0K | $2.08 | $166K | SEC | |
| Goodman Noah | Chief Business Officer | S — Open-market sale | 3.4K | $114.29 | $387K | SEC | |
| Mainolfi Nello | Chief Executive Officer | S — Open-market sale | 6.6K | $113.98 | $755K | SEC | |
| Mainolfi Nello | Chief Executive Officer | S — Open-market sale | 3.3K | $116.56 | $389K | SEC | |
| Mainolfi Nello | Chief Executive Officer | S — Open-market sale | 44.0K | $115.69 | $5.10M | SEC | |
| Mainolfi Nello | Chief Executive Officer | S — Open-market sale | 24.1K | $114.96 | $2.77M | SEC | |
| Jacobs Bruce N. | Chief Financial Officer | S — Open-market sale | 3.2K | $117.70 | $377K | SEC | |
| Jacobs Bruce N. | Chief Financial Officer | S — Open-market sale | 6.2K | $116.99 | $720K | SEC | |
| Jacobs Bruce N. | Chief Financial Officer | S — Open-market sale | 4.1K | $114.19 | $469K | SEC | |
| Jacobs Bruce N. | Chief Financial Officer | S — Open-market sale | 1.1K | $112.79 | $124K | SEC | |
| Jacobs Bruce N. | Chief Financial Officer | S — Open-market sale | 51.4K | $114.77 | $5.90M | SEC | |
| Jacobs Bruce N. | Chief Financial Officer | S — Open-market sale | 1.5K | $110.54 | $166K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Kymera Therapeutics, Inc. (KYMR). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Booth Bruce | 83 | $92.67M |
| Mainolfi Nello | 16 | $17.94M |
| Jacobs Bruce N. | 14 | $9.25M |
| Chadwick Jeremy G | 12 | $1.41M |
| Goodman Noah | 8 | $1.36M |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in KYMR insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live KYMR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.